200 related articles for article (PubMed ID: 32945520)
61. ABCG2-overexpressing S1-M1-80 cell xenografts in nude mice keep original biochemistry and cell biological properties.
Wang F; Liang YJ; Wu XP; Su XD; Fu LW
Chin J Cancer; 2012 Mar; 31(3):150-8. PubMed ID: 22360854
[TBL] [Abstract][Full Text] [Related]
62. MiR-548 K regulatory effect on the ABCG2 gene expression in MDR breast cancer cells.
Saberiyan M; Ghasemi Z; Yaghoobi H
Cancer Rep (Hoboken); 2023 Jun; 6(6):e1816. PubMed ID: 37166017
[TBL] [Abstract][Full Text] [Related]
63. Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.
Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
Mol Pharm; 2019 Jul; 16(7):3040-3052. PubMed ID: 31117741
[TBL] [Abstract][Full Text] [Related]
64. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
Sen R; Natarajan K; Bhullar J; Shukla S; Fang HB; Cai L; Chen ZS; Ambudkar SV; Baer MR
Mol Cancer Ther; 2012 Sep; 11(9):2033-44. PubMed ID: 22778153
[TBL] [Abstract][Full Text] [Related]
65. YAP1 regulates ABCG2 and cancer cell side population in human lung cancer cells.
Dai Y; Liu S; Zhang WQ; Yang YL; Hang P; Wang H; Cheng L; Hsu PC; Wang YC; Xu Z; Jablons DM; You L
Oncotarget; 2017 Jan; 8(3):4096-4109. PubMed ID: 27911857
[TBL] [Abstract][Full Text] [Related]
66. siRNAs targeting multidrug transporter genes sensitise breast tumour to doxorubicin in a syngeneic mouse model.
Tiash S; Chowdhury EH
J Drug Target; 2019 Mar; 27(3):325-337. PubMed ID: 30221549
[TBL] [Abstract][Full Text] [Related]
67. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
[TBL] [Abstract][Full Text] [Related]
68. Effects of long noncoding RNA (linc-VLDLR) existing in extracellular vesicles on the occurrence and multidrug resistance of esophageal cancer cells.
Chen Y; Liu L; Li J; Du Y; Wang J; Liu J
Pathol Res Pract; 2019 Mar; 215(3):470-477. PubMed ID: 30606658
[TBL] [Abstract][Full Text] [Related]
69. GPER mediates decreased chemosensitivity via regulation of ABCG2 expression and localization in tamoxifen-resistant breast cancer cells.
Yu T; Cheng H; Ding Z; Wang Z; Zhou L; Zhao P; Tan S; Xu X; Huang X; Liu M; Peng M; Qiu YA
Mol Cell Endocrinol; 2020 Apr; 506():110762. PubMed ID: 32087276
[TBL] [Abstract][Full Text] [Related]
70. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
Xu J; Wu J; Fu C; Teng F; Liu S; Dai C; Shen R; Jia X
J Cell Physiol; 2018 Jun; 233(6):5034-5043. PubMed ID: 29219179
[TBL] [Abstract][Full Text] [Related]
71. Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype.
Singh A; Wu H; Zhang P; Happel C; Ma J; Biswal S
Mol Cancer Ther; 2010 Aug; 9(8):2365-76. PubMed ID: 20682644
[TBL] [Abstract][Full Text] [Related]
72. An organoruthenium complex overcomes ABCG2-mediated multidrug resistance via multiple mechanisms.
Zeng L; Li J; Zhang C; Zhang YK; Zhang W; Huang J; Ashby CR; Chen ZS; Chao H
Chem Commun (Camb); 2019 Mar; 55(26):3833-3836. PubMed ID: 30869688
[TBL] [Abstract][Full Text] [Related]
73. SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines.
Wu CP; Murakami M; Hsiao SH; Liu TC; Yeh N; Li YQ; Hung TH; Wu YS; Ambudkar SV
Cancer Lett; 2018 Oct; 433():259-272. PubMed ID: 30026175
[TBL] [Abstract][Full Text] [Related]
74. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Shukla S; Ambudkar SV; Kong D; Chen ZS
Cancer Lett; 2019 Jan; 440-441():82-93. PubMed ID: 30315846
[TBL] [Abstract][Full Text] [Related]
75. PCI29732, a Bruton's Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells.
Ge C; Wang F; Cui C; Su X; To KKW; Wang X; Zhang H; Song X; Fu L
Cell Physiol Biochem; 2018; 48(6):2302-2317. PubMed ID: 30114704
[TBL] [Abstract][Full Text] [Related]
76. A Phenylfurocoumarin Derivative Reverses ABCG2-Mediated Multidrug Resistance In Vitro and In Vivo.
Kokubo S; Ohnuma S; Murakami M; Kikuchi H; Funayama S; Suzuki H; Kajiwara T; Yamamura A; Karasawa H; Sugisawa N; Ohsawa K; Kano K; Aoki J; Doi T; Naitoh T; Ambudkar SV; Unno M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830383
[TBL] [Abstract][Full Text] [Related]
77. Noninvasive Evaluation of Multidrug Resistance via Imaging of ABCG2/BCRP Multidrug Transporter in Lung Cancer Xenograft Models.
Li C; Yang Q; Chen Z; Qiu Y; Du Y; Wang R; He Q; Yang J; Zhen H; Kang L
Mol Pharm; 2022 Oct; 19(10):3521-3529. PubMed ID: 35427142
[TBL] [Abstract][Full Text] [Related]
78. OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance.
Kuang YH; Patel JP; Sodani K; Wu CP; Liao LQ; Patel A; Tiwari AK; Dai CL; Chen X; Fu LW; Ambudkar SV; Korlipara VL; Chen ZS
Biochem Pharmacol; 2012 Sep; 84(6):766-74. PubMed ID: 22750060
[TBL] [Abstract][Full Text] [Related]
79. AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
Zhang H; Wang YJ; Zhang YK; Wang DS; Kathawala RJ; Patel A; Talele TT; Chen ZS; Fu LW
Cancer Lett; 2014 Aug; 350(1-2):61-8. PubMed ID: 24747122
[TBL] [Abstract][Full Text] [Related]
80. Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression.
Orlando UD; Castillo AF; Medrano MAR; Solano AR; Maloberti PM; Podesta EJ
Biochem Pharmacol; 2019 Jan; 159():52-63. PubMed ID: 30414939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
